
浏览全部资源
扫码关注微信
1.重庆医科大学基础医学院病理学教研室,重庆 400016
2.重庆医科大学附属第一医院第一分院消化内科,重庆 400016
贺 娟,Email:1695137674@qq.com,研究方向:淋巴造血系统肿瘤病理方向。
李 丹,Email: lidancq@cqmu.edu.cn。
收稿:2024-04-23,
修回:2024-05-20,
录用:2024-05-30,
纸质出版:2024-07-28
移动端阅览
贺娟,王星宇,何鸿,等.淋巴结滤泡辅助T细胞淋巴瘤-血管免疫母细胞型临床病理特征和预后因素分析[J].重庆医科大学学报,2024,49(7):895-903.
He Juan,Wang Xingyu,He Hong,et al.Clinicopathological features and prognostic factors of nodal T-follicular helper cell lymphoma,angioimmunoblastic-type[J].Journal of Chongqing Medical University,2024,49(7):895-903.
贺娟,王星宇,何鸿,等.淋巴结滤泡辅助T细胞淋巴瘤-血管免疫母细胞型临床病理特征和预后因素分析[J].重庆医科大学学报,2024,49(7):895-903. DOI: 10.13406/j.cnki.cyxb.003547.
He Juan,Wang Xingyu,He Hong,et al.Clinicopathological features and prognostic factors of nodal T-follicular helper cell lymphoma,angioimmunoblastic-type[J].Journal of Chongqing Medical University,2024,49(7):895-903. DOI: 10.13406/j.cnki.cyxb.003547.
目的
2
探讨淋巴结滤泡辅助T细胞淋巴瘤-血管免疫母细胞型(nodal T-follicular helper cell lymphoma,angioimmuno-blastic-type,nTFHL-AI)临床病理特征和预后因素。
方法
2
回顾性分析63例nTFHL-AI患者临床信息,利用免疫组化(immunohistochemistry,IHC)、原位杂交(in situ hybridization,ISH)和抗原受体基因重排评估nTFHL-AI临床病理特征。使用Cox比例风险回归模型评估预后因素。
结果
2
免疫染色提示CD4阳性肿瘤细胞例数明显超过CD8(66% vs. 5%)。Epstein-Barr病毒(Epstein-Barr virus,EBV)编码的小RNA(EBV-encoded small RNA,EBER)阳性患者比EBER阴性患者更易表达CXCL13(
P
=0.006)。5年总体生存期(overall survival,OS)和无进展生存期(progression-free survival,PFS)分别为31%和16%。CXCL13阳性组OS和PFS显著优于CXCL13阴性组(
P
=0.003、
P
=0.04
0)。相反,BCL6阳性表达与较差的OS和PFS相关(
P
=0.026、
P
= 0.044),EBER阴性也与较差的OS和PFS相关(
P
=0.013、
P
=0.047)。多因素分析表明EBER阴性是OS和PFS独立不良预后因素(
P
=0.001、
P
=0.003)。
结论
2
CXCL13阳性预示nTFHL-AI患者预后良好,而BCL6阳性和EBER阴性与患者预后不良相关,并且EBER阴性是患者预后的独立危险因素。
Objective
2
To investigate the clinicopathologic features and prognostic factors of nodal T-follicular helper cell lymphoma,angioimmunoblastic-type(nTFHL-AI).
Methods
2
A retrospective analysis was performed for the clinical information of 63 patients with nTFHL-AI,and immunohistochemistry,
in situ
hybridization,and antigen receptor gene rearrangement were used to assess the clinicopathological features of nTFHL-AI. The
Cox
proportional hazards regression model was used to investigate prognostic factors.
Results
2
Immunostaining showed that the number of patients with dominant CD4-positive cells was significantly higher than that of patients with dominant CD8-positive cells(66% vs. 5%). The patients who tested positive for Epstein-Barr virus-encoded small RNA (EBER) showed a higher probability for the expression of CXCL13 compared with their EBER-negative counterparts(
P
=0.006). The 5-year overall survival(OS) rate and the progression-free survival(PFS) rate were 31% and 16%,respectively. The CXCL13-positive group had significantly better OS and PFS than the CXCL13-negative group(
P
=0.003 and 0.040). On the contrary,positive BCL6 expression was associated with worse OS and PFS(
P
=0.026 and 0.044),and negative EBER was also associated with worse OS and PFS(
P
=0.013 and 0.047). The multivariate analysis showed that negative EBER was an independent negative prognostic factor for both OS and PFS(
P
=0.001 and 0.003).
Conclusion
2
Positive expression of CXCL13 indicates a favorable prognosis of nTFHL-AI patients,while positive BCL6 and negative EBER are associated with poor prognosis,and negative EBER is an independent risk factor for the prognosis of patients.
Lunning MA , Vose JM . Angioimmunoblastic T-cell lymphoma:the many-faced lymphoma [J ] . Blood , 2017 , 129 ( 9 ): 1095 - 1102 .
Vose J , Armitage J , Weisenburger D , et al . International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes [J ] . J Clin Oncol , 2008 , 26 ( 25 ): 4124 - 4130 .
Alaggio R , Amador C , Anagnostopoulos I , et al . The 5th edition of the World Health Organization classification of haematolymphoid tumours:lymphoid neoplasms [J ] . Leukemia , 2022 , 36 ( 7 ): 1720 - 1748 .
Chiba S , Sakata-Yanagimoto M . Advances in understanding of angioimmunoblastic T-cell lymphoma [J ] . Leukemia , 2020 , 34 ( 10 ): 2592 - 2606 .
Lachenal F , Berger F , Ghesquières H , et al . Angioimmunoblastic T-cell lymphoma [J ] . Medicine , 2007 , 86 ( 5 ): 282 - 292 .
Mourad N , Mounier N , Brière J , et al . Clinical,biologic,and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials [J ] . Blood , 2008 , 111 ( 9 ): 4463 - 4470 .
Dunleavy K , Wilson WH , Jaffe ES . Angioimmunoblastic T cell lymphoma:pathobiological insights and clinical implications [J ] . Curr Opin Hematol , 2007 , 14 ( 4 ): 348 - 353 .
Xie Y , Jaffe ES . How I diagnose angioimmunoblastic T-cell lymphoma [J ] . Am J Clin Pathol , 2021 , 156 ( 1 ): 1 - 14 .
He XY , Xu P , Wang XW , et al . The association of gene rearrangement and lymphoma diagnosis:a prospective observational study [J ] . Medicine , 2020 , 99 ( 24 ): e20733 .
Cheson BD , Fisher RI , Barrington SF , et al . Recommendations for initial evaluation,staging,and response assessment of Hodgkin and non-Hodgkin lymphoma:the Lugano classification [J ] . J Clin Oncol , 2014 , 32 ( 27 ): 3059 - 3068 .
Eladl AE , Shimada K , Suzuki Y , et al . EBV status has prognostic implication among young patients with angioimmunoblastic T-cell lymphoma [J ] . Cancer Med , 2020 , 9 ( 2 ): 678 - 688 .
Basha BM , Bryant SC , Rech KL , et al . Application of a 5 marker panel to the routine diagnosis of peripheral T-cell lymphoma with T-follicular helper phenotype [J ] . Am J Surg Pathol , 2019 , 43 ( 9 ): 1282 - 1290 .
Bahri R , Boyer F , Halabi MA , et al . Epstein-barr virus(EBV) is mostly latent and clonal in angioimmunoblastic T cell lymphoma(AITL) [J ] . Cancers , 2022 , 14 ( 12 ): 2899 .
Dobay MP , Lemonnier F , Missiaglia E , et al . Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin [J ] . Haematologica , 2017 , 102 ( 4 ): e148 - e151 .
Chen HZ , Tao YX , Zhou Y , et al . The clinical features,treatment,and prognostic factors for peripheral T-cell lymphomas:a single-institution analysis of 240 Chinese patients [J ] . Asia Pac J Clin Oncol , 2023 , 19 ( 5 ): e202 - e214 .
de Leval L , Parrens M , Le Bras F , et al . Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets [J ] . Haematologica , 2015 , 100 ( 9 ): e361 - e364 .
Wei C , Li W , Qin LP , et al . Clinicopathologic characteristics,outcomes,and prognostic factors of angioimmunoblastic T-cell lymphoma in China [J ] . Cancer Med , 2023 , 12 ( 4 ): 3987 - 3998 .
Advani RH , Skrypets T , Civallero M , et al . Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma:final report from the international T-cell Project [J ] . Blood , 2021 , 138 ( 3 ): 213 - 220 .
Cortés JR , Palomero T . The curious origins of angioimmunoblastic T-cell lymphoma [J ] . Curr Opin Hematol , 2016 , 23 ( 4 ): 434 - 443 .
Lage LAPC , Culler HF , Reichert CO , et al . Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype:from molecular mechanisms to therapeutic advances [J ] . Front Oncol , 2023 , 13 : 1177590 .
Joshi K , Liu SH , Peter Breslin SJ , et al . Mechanisms that regulate the activities of TET proteins [J ] . Cell Mol Life Sci , 2022 , 79 ( 7 ): 363 .
Nishizawa S , Sakata-Yanagimoto M , Hattori K , et al . BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma [J ] . Int J Hematol , 2017 , 105 ( 4 ): 465 - 469 .
Crichton ES , Zeng S , 2nd La Muraglia GM , et al . CXCL13 is an indicator of germinal center activity and alloantibody formation following transplantation [J ] . Transplant Direct , 2021 , 7 ( 12 ): e785 .
Kim TY , Min GJ , Jeon YW , et al . Impact of epstein-barr virus on peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma [J ] . Front Oncol , 2021 , 11 : 797028 .
Liang JH , Lu L , Zhu HY , et al . The prognostic role of circulating epstein-barr virus DNA copy number in angioimmunoblastic T-cell lymphoma treated with dose-adjusted EPOCH [J ] . Cancer Res Treat , 2019 , 51 ( 1 ): 150 - 157 .
Dunleavy K , Wilson WH . Angioimmunoblastic T-cell lymphoma:immune modulation as a therapeutic strategy [J ] . Leuk Lymphoma , 2007 , 48 ( 3 ): 449 - 451 .
0
浏览量
4
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621